CoChat

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma

Open access

Abstract

BACKGROUND: Intratumoral heterogeneity hampers the success of marker-based anticancer treatment because the targeted therapy may eliminate a specific subpopulation of tumor cells while leaving others unharmed. Accordingly, a rational strategy minimizing survival of the drug-resistant subpopulation is essential to achieve long-term therapeutic efficacy. RESULTS: Using single-cell RNA sequencing (RNA-seq), we examine the intratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis. Activation of drug target pathways demonstrates considerable variability between the primary and metastatic sites, as well as among individual cancer cells within each site. Based on the prediction of multiple drug target pathway activation, we derive a combinatorial regimen co-targeting two mutually exclusive pathways for the metastatic cancer cells. This combinatorial strategy shows significant increase in the treatment efficacy over monotherapy in the experimental validation using patient-derived xenograft platforms in vitro and in vivo. CONCLUSIONS: Our findings demonstrate the investigational application of single-cell RNA-seq in the design of an anticancer regimen. The approach may overcome intratumoral heterogeneity which hampers the success of precision medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13059-016-0945-9

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Profiling transcriptome of paired pRCC and mRCC at single-cell resolution. a Brief description of clinical course in a patient with metastatic RCC. b Schematic of scRNA-seq experiments from establishment of the patient-derived xenograft model to discovery of targetable subpopulations. c Hierarchical clustering heatmap and dendrogram based on inter-correlation of centroid global expression profiles across kidney cortex normal, bulk cells of each population, and single cells using Euclidean distance metric and average linkage. d Principal component analysis (PCA) of single-cell-resolved gene expression profiles based on the first two principal components. Ellipses represent 95 % confidence around each group
Fig. 1 Profiling transcriptome of paired pRCC and mRCC at single-cell resolution. a Brief description of clinical course in a patient with metastatic RCC. b Schematic of scRNA-seq experiments from establishment of the patient-derived xenograft model to discovery of targetable subpopulations. c Hierarchical clustering heatmap and dendrogram based on inter-correlation of centroid global expression profiles across kidney cortex normal, bulk cells of each population, and single cells using Euclidean distance metric and average linkage. d Principal component analysis (PCA) of single-cell-resolved gene expression profiles based on the first two principal components. Ellipses represent 95 % confidence around each groupCC BY · PubMed Central
Fig. 2 Evaluation of expression signatures associated with metastatic RCC across single cells. a–d Gene set activation analysis for the metastatic signature (a and b) and clear cell RCC prognostic signature (c and d). a, c Positions of each dot and ellipse in Fig. 1d were fixed, and then each dot was colored (main panel) and indicated as drop lines (top and right panels) according to the estimated status for the given signatures. Gene Set Variation Analysis (GSVA) scores were normalized to normal kidney tissue expression profiles. b, d Boxplots show overall reciprocal differences in the expression signatures across normal kidney cortex, bulk cells of each population, and single cells. Boxes show 25th to 75th percentile with 10th and 90th percentile whiskers. *P <0.05, **P <0.01, ***P <0.001, two-tailed Student’s t-test
Fig. 2 Evaluation of expression signatures associated with metastatic RCC across single cells. a–d Gene set activation analysis for the metastatic signature (a and b) and clear cell RCC prognostic signature (c and d). a, c Positions of each dot and ellipse in Fig. 1d were fixed, and then each dot was colored (main panel) and indicated as drop lines (top and right panels) according to the estimated status for the given signatures. Gene Set Variation Analysis (GSVA) scores were normalized to normal kidney tissue expression profiles. b, d Boxplots show overall reciprocal differences in the expression signatures across normal kidney cortex, bulk cells of each population, and single cells. Boxes show 25th to 75th percentile with 10th and 90th percentile whiskers. *P <0.05, **P <0.01, ***P <0.001, two-tailed Student’s t-testCC BY · PubMed Central
Fig. 3 Identification of targetable signaling pathways by transcriptome profiling and drug screening. a Quantitative estimation of the activation status of targetable signaling pathways across single cells. Boxplots demonstrate overall reciprocal differences in expression signatures across normal kidney cortex, bulk cells of each population, and single cells. b Measured drug response profiles of pRCC and mRCC cells, matched to the targetable signaling pathways. Sensitivities of cells to various targeted drugs were determined based on the half-maximal inhibitory concentration (IC50), and transformed to Z-scores. Afatinib and dasatinib were selected as the most effective drugs against mRCC cells (denoted as *) whereas everolimus and pazopanib (denoted as †) showed no effects, which is consistent with clinical findings. c–e Drug sensitivity was predicted by the ridge regression model using a training set of publicly available cancer cell line expression data with each of the measured IC50 data. Estimated values were transformed to Z-scores across samples. c Significant correlation of predicted drug sensitivity with measured sensitivity in b. d Comparison of the predicted drug sensitivity of afatinib and dasatinib between populations. e For the selected drugs afatinib and dasatinib, there was a significant correlation between predicted drug sensitivity (Z-scores) and activation status (GSVA scores) of the relevant targeted pathways. c, e Linear regression was applied to estimate Pearson’s correlation coefficient (r), with 95 % confidence as shown by thicker light gray curves. The statistical significance of the regression was determined by one-way ANOVA test. a, d Boxes show 25th to 75th percentile with 10th and 90th percentile whiskers. *P <0.05, **P <0.01, ***P <0.001, two-tailed Student’s t-test
Fig. 3 Identification of targetable signaling pathways by transcriptome profiling and drug screening. a Quantitative estimation of the activation status of targetable signaling pathways across single cells. Boxplots demonstrate overall reciprocal differences in expression signatures across normal kidney cortex, bulk cells of each population, and single cells. b Measured drug response profiles of pRCC and mRCC cells, matched to the targetable signaling pathways. Sensitivities of cells to various targeted drugs were determined based on the half-maximal inhibitory concentration (IC50), and transformed to Z-scores. Afatinib and dasatinib were selected as the most effective drugs against mRCC cells (denoted as *) whereas everolimus and pazopanib (denoted as †) showed no effects, which is consistent with clinical findings. c–e Drug sensitivity was predicted by the ridge regression model using a training set of publicly available cancer cell line expression data with each of the measured IC50 data. Estimated values were transformed to Z-scores across samples. c Significant correlation of predicted drug sensitivity with measured sensitivity in b. d Comparison of the predicted drug sensitivity of afatinib and dasatinib between populations. e For the selected drugs afatinib and dasatinib, there was a significant correlation between predicted drug sensitivity (Z-scores) and activation status (GSVA scores) of the relevant targeted pathways. c, e Linear regression was applied to estimate Pearson’s correlation coefficient (r), with 95 % confidence as shown by thicker light gray curves. The statistical significance of the regression was determined by one-way ANOVA test. a, d Boxes show 25th to 75th percentile with 10th and 90th percentile whiskers. *P <0.05, **P <0.01, ***P <0.001, two-tailed Student’s t-testCC BY · PubMed Central
Fig. 4 Dissection of single-cell subpopulations according to distinctive activation status of EGFR and Src pathways. a, b Single cells were manually ordered by categorization into four groups according to their activation status as shown in e. a Heatmaps showing the relative (upper) and binary (lower) activation status for EGFR and Src pathways in mRCC cells from parental and PDX tumors. b Predicted drug sensitivity of afatinib and dasatinib matched to a. c Comparison of the fraction of categorized single cells between parental and PDX tumors. d Differences in the estimated pathways with predicted drug sensitivity among the four classified groups. Boxes show 25th to 75th percentile with 10th and 90th percentile whiskers. *P <0.05, **P <0.01, ***P <0.001, two-tailed Student’s t-test. e Strategic combination therapy using afatinib and dasatinib to target the EGFR and Src signaling pathways, respectively
Fig. 4 Dissection of single-cell subpopulations according to distinctive activation status of EGFR and Src pathways. a, b Single cells were manually ordered by categorization into four groups according to their activation status as shown in e. a Heatmaps showing the relative (upper) and binary (lower) activation status for EGFR and Src pathways in mRCC cells from parental and PDX tumors. b Predicted drug sensitivity of afatinib and dasatinib matched to a. c Comparison of the fraction of categorized single cells between parental and PDX tumors. d Differences in the estimated pathways with predicted drug sensitivity among the four classified groups. Boxes show 25th to 75th percentile with 10th and 90th percentile whiskers. *P <0.05, **P <0.01, ***P <0.001, two-tailed Student’s t-test. e Strategic combination therapy using afatinib and dasatinib to target the EGFR and Src signaling pathways, respectivelyCC BY · PubMed Central
Fig. 5 Effective combinatorial strategy targeting heterogeneous subclones in mRCC. a, b Combined effects of afatinib and dasatinib on viability of mRCC cells were analyzed 6 days after treatment under 2D non-adherent culture conditions a or 3D ECM scaffold culture system b. c Effects of afatinib and dasatinib combination therapy on EGFR and Src downstream pathways were validated by immunoblotting. Cells were incubated with 0.5 μM afatinib and/or dasatinib for 1 h. GAPDH = loading control. Cells that were mock-treated with 0.5 μM DMSO served as negative controls. Error bar = SEM (n = 3 for each group). **P <0.01, ***P <0.001. d–i Superior antitumor efficacy of combinations of afatinib and dasatinib in mRCC subcutaneous xenografts. d Mice bearing mRCC tumors (=5 mice/group) were p.o. dosed with afatinib (each at 20 mg/kg) or i.p. administered dasatinib (each at 15 mg/kg), either alone or in combination, on a daily dosing regimen for up to 15 days. Growth curves based on tumor volumes are shown as the mean ± SEM for each time point. *P <0.05, **P <0.01. e Changes in body weight of mice treated with afatinib and/or dasatinib. Body weight was measured on the indicated days. Data show mean ± SEM. Tumor tissues from each group were harvested on day 15 and subjected to immunoblot analysis with the indicated antibodies to detect p-EGFR, p-Src, and p-AKT (f; GAPDH = loading control), or immunostained with anti-p-ERK antibody g. Proliferation and apoptotic rates in each group were determined by Ki-67 immunostaining h and TUNEL assay i. Results are presented as mean values ± SEM. *P <0.05, ***P <0.001. Scale bars = 100 μm
Fig. 5 Effective combinatorial strategy targeting heterogeneous subclones in mRCC. a, b Combined effects of afatinib and dasatinib on viability of mRCC cells were analyzed 6 days after treatment under 2D non-adherent culture conditions a or 3D ECM scaffold culture system b. c Effects of afatinib and dasatinib combination therapy on EGFR and Src downstream pathways were validated by immunoblotting. Cells were incubated with 0.5 μM afatinib and/or dasatinib for 1 h. GAPDH = loading control. Cells that were mock-treated with 0.5 μM DMSO served as negative controls. Error bar = SEM (n = 3 for each group). **P <0.01, ***P <0.001. d–i Superior antitumor efficacy of combinations of afatinib and dasatinib in mRCC subcutaneous xenografts. d Mice bearing mRCC tumors (=5 mice/group) were p.o. dosed with afatinib (each at 20 mg/kg) or i.p. administered dasatinib (each at 15 mg/kg), either alone or in combination, on a daily dosing regimen for up to 15 days. Growth curves based on tumor volumes are shown as the mean ± SEM for each time point. *P <0.05, **P <0.01. e Changes in body weight of mice treated with afatinib and/or dasatinib. Body weight was measured on the indicated days. Data show mean ± SEM. Tumor tissues from each group were harvested on day 15 and subjected to immunoblot analysis with the indicated antibodies to detect p-EGFR, p-Src, and p-AKT (f; GAPDH = loading control), or immunostained with anti-p-ERK antibody g. Proliferation and apoptotic rates in each group were determined by Ki-67 immunostaining h and TUNEL assay i. Results are presented as mean values ± SEM. *P <0.05, ***P <0.001. Scale bars = 100 μmCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 71 references

Cited by

See all 198

Metadata

Authors
Kim, K.-T., Lee, H. W., Lee, H.-O., Song, H. J., Jeong, D. E., Shin, S., Kim, H., Shin, Y., Nam, D.-H., Jeong, B. C., Kirsch, D. G., Joo, K. M., & Park, W.-Y.
Affiliations
  • Samsung Medical Center (KR)
  • Sungkyunkwan University (KR)
  • Korea University (KR)
  • Duke University (US)
Corresponding author
  • Joo, Kyeung Min
  • Park, Woong-Yang
Venue
Genome Biology
Published
2016-04-29
Volume
17
Issue
1
Pages
80-80
ISSN
  • 1465-6906 (ISSN-L)
  • 1474-760X
OpenAlex
W2342423616
Cited by
198
References
71
Citations by year
2026: 5 · 2025: 8 · 2024: 12 · 2023: 20 · 2022: 21 · 2021: 35 · 2020: 27 · 2019: 19 · 2018: 23 · 2017: 21 · 2016: 7
FWCI
20.70
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Genome biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Korea National Institute of Health (HI13C2096000013)
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
Keywords
metastatic renal cell carcinoma, intratumoral heterogeneity, lung metastasis, drug resistance, combination therapy, patient-derived xenografts, precision medicine, single-cell RNA sequencing
MeSH terms
Adult, Animals, Carcinoma, Renal Cell, Cells, Cultured, Humans, Kidney Neoplasms, Lung Neoplasms, Male, Sequence Analysis, RNA, Gene Expression Profiling, Mice, Molecular Targeted Therapy, Single-Cell Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. https://app.cochat.ai/papers/10.1186/s13059-016-0945-9
The paper
Kim, K.-T., Lee, H. W., Lee, H.-O., Song, H. J., Jeong, D. E., Shin, S., Kim, H., Shin, Y., Nam, D.-H., Jeong, B. C., Kirsch, D. G., Joo, K. M., & Park, W.-Y. (2016). Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biology. https://doi.org/10.1186/s13059-016-0945-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.